GILD - Gilead Sciences, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
+1.81 (+2.73%)
At close: 4:00PM EDT

68.05 -0.02 (-0.03%)
After hours: 6:00PM EDT

Stock chart is not supported by your current browser
Previous Close66.26
Bid68.07 x 2200
Ask68.09 x 800
Day's Range66.84 - 68.24
52 Week Range60.32 - 79.61
Avg. Volume6,566,001
Market Cap86.554B
Beta (3Y Monthly)1.15
PE Ratio (TTM)15.02
EPS (TTM)4.53
Earnings DateJul 30, 2019
Forward Dividend & Yield2.52 (3.80%)
Ex-Dividend Date2019-06-13
1y Target Est79.62
Trade prices are not sourced from all markets
  • GuruFocus.com36 minutes ago

    Wall Street Mixed on Monday

    Galapagos skyrockets to an all-time high Continue reading...

  • What Happened in the Stock Market Today
    Motley Fool1 hour ago

    What Happened in the Stock Market Today

    From failed takeover talks to a massive new partnership, see why these stocks were on the move on a quiet day for the broader markets.

  • Gilead Stock Is Among The Biggest Biotech Stocks — But Should You Buy It?
    Investor's Business Daily2 hours ago

    Gilead Stock Is Among The Biggest Biotech Stocks — But Should You Buy It?

    Gilead is one of the biggest biotech companies. But recent news and earnings have been mixed. So, is Gilead stock a buy right now? Read on for a full analysis.

  • Gilead Pens $5 Billion Research Deal — Why Analysts Still Want A Merger
    Investor's Business Daily2 hours ago

    Gilead Pens $5 Billion Research Deal — Why Analysts Still Want A Merger

    Galapagos stock rocketed to an all-time high Monday on a deeper $5.05 billion research and development deal with giant biotech company Gilead Sciences. Gilead stock also gained on the news.

  • Gilead Sciences Expands Collaboration with Galapagos
    Market Realist4 hours ago

    Gilead Sciences Expands Collaboration with Galapagos

    On July 14, Gilead Sciences announced that it will expand its collaboration with Galapagos (GLPG).

  • Will Gilead Sciences Stock Really Rally 33% From Here?
    TheStreet.com7 hours ago

    Will Gilead Sciences Stock Really Rally 33% From Here?

    Shares of Gilead Sciences are jumping higher on its increased investment in Galapagos and a new outperform rating from Wells Fargo.

  • Gilead Risks Regrets on Pricey Galapagos Partnership
    Bloomberg8 hours ago

    Gilead Risks Regrets on Pricey Galapagos Partnership

    (Bloomberg Opinion) -- Gilead Sciences Inc.’s new CEO Daniel O'Day is trying to replicate the successful playbook of his former employer Roche Holding AG, the Swiss pharma giant he worked at for more than 30 years. On Sunday, Gilead announced that it would invest $5.1 billion to deepen an existing relationship with Belgian biotechnology firm Galapagos NV. O'Day isn't just committing to Galapagos – he’s committing to the idea of research partnerships that stop short of outright M&A. The deal includes a 10-year standstill agreement that restricts Gilead's ability to acquire the company. O'Day thinks that leaving Galapagos independent will keep it innovative, a bet that paid off for Roche and its productive long-term partnerships with Genentech and Chugai Pharmaceutical Co. That nebulous benefit will have to come through in a big way to justify the price and structure of this deal.  Gilead is paying $3.4 billion upfront to gain rights to six drugs in clinical trials and access to a suite of earlier-stage programs. It is also making a $1.1 billion equity investment in Galapagos.The total outlay is a scant $2 billion less than the market cap of Galapagos before the deal was announced, and is above what the company was worth as recently as March.  On top of that, Gilead already owned 12 percent of Galapagos and rights to potential blockbuster arthritis drug filgotinib from a $725 million deal completed in 2015. O'Day also isn't done paying up. He will have to shell out more cash to opt in to future programs and for development costs. Gilead will also pay a significant sales royalty if any drugs are approved. And Galapagos will retain European rights for most of its medicines. The potential return of this deal is lower than an outright acquisition, and Gilead didn't seem to get much of a discount. It’s giving up a lot to limit its risk and test the abstract notion that partnerships are superior. The company's late-stage pipeline is sparse, and it is too reliant on its HIV franchise. It’s not in a position to leave upside on the table. There’s a chance that the deal could work out. Gilead’s only has to pay $150 million to gain exposure to programs that are currently in early stages; that could wind up being a relative steal at some point in the next decade. Investors may feel a twinge with every opt-in and royalty check, however. Gilead had chances during the past few years to acquire Galapagos at a lower price than what it’s paying for the partnership now. That feels like a missed opportunity, and may seem even more so if its  pipeline and R&D platform turn out to be as strong as O’Day seems to think they are.To contact the author of this story: Max Nisen at mnisen@bloomberg.netTo contact the editor responsible for this story: Beth Williams at bewilliams@bloomberg.netThis column does not necessarily reflect the opinion of the editorial board or Bloomberg LP and its owners.Max Nisen is a Bloomberg Opinion columnist covering biotech, pharma and health care. He previously wrote about management and corporate strategy for Quartz and Business Insider.For more articles like this, please visit us at©2019 Bloomberg L.P.

  • Benzinga8 hours ago

    Galapagos Notches $3.95B Upfront Investment From Gilead

    Gilead said it will make a $3.95-billion upfront payment and $1.1-billion equity investment in the Belgian pharmaceutical company, according to a Sunday press release. Galapagos intends to use the proceeds to expand its research and development programs. As part of a 10-year global research and development collaboration; Gilead will have access to a portfolio of compounds, including six molecules in clinical trials, more than 20 preclinical programs and a drug discovery platform. Galapagos shares were trading higher by 16.34% at $169.56 at the time of publication.

  • How Gilead's $5.1 billion deal could steal a page from Genentech-Roche hookup
    American City Business Journals8 hours ago

    How Gilead's $5.1 billion deal could steal a page from Genentech-Roche hookup

    Daniel O'Day watched as Roche, where he was a top executive, took a piece of Genentech, then ultimately bought the South San Francisco company. Now as the chairman and CEO of Foster City-based Gilead Sciences, a deal with a Belgian biotech feels similar.

  • Barrons.com9 hours ago

    Gilead Sciences Says No to Megamerger, Signs a Deal to Collaborate With Galapagos

    Shares of the European drugmaker Galapagos are soaring after (GILD) said over the weekend that it would spend $5 billion on a collaboration agreement with the firm. Instead of embarking on a pharmaceutical megamerger, of the sort Barron’s has argued against, Daniel O’Day, Gilead’s new CEO, signed a 10-year deal with longtime collaborator Galapagos (ticker: GLPG) to boost his company’s pipeline of potential treatments. “I firmly believe [in] the concept that we’ve come up with, the concept of enabling Galapagos with a significant capital infusion for them to further invest in that research and at the same time keeping their independence as a premier European biotech company that allows them to recruit the very best talent, make their own decision and progress programs according to their judgment,” O’Day said on a conference call about the deal.

  • Why Galapagos NV Stock Is Soaring Today
    Motley Fool9 hours ago

    Why Galapagos NV Stock Is Soaring Today

    Gilead Sciences decided to inject $5.1 billion into its R&D partner Galapagos NV over the weekend.

  • Gilead-Galapagos Ink $5.1B Deal for Additional Compounds
    Zacks9 hours ago

    Gilead-Galapagos Ink $5.1B Deal for Additional Compounds

    Gilead (GILD) collaborates with Galapagos for additional compounds for $5.1 billion and ups its stake in the latter to 22%.

  • AI Drug Hunters Could Give Big Pharma a Run for Its Money
    Bloomberg11 hours ago

    AI Drug Hunters Could Give Big Pharma a Run for Its Money

    (Bloomberg) -- Machine-learning technology has beaten humans at games of chess and Go to worldwide fanfare. A demonstration of its eerily lifelike prowess in making phone calls to unsuspecting people went viral.But a less-noticed win for DeepMind, the artificial-intelligence arm of Google’s parent Alphabet Inc., at a biennial biology conference could upend how drugmakers find and develop new medicines. It could also dial up pressure on the world’s largest pharmaceutical companies to prepare for a technological arms race. Already, a new breed of upstarts are jumping into the fray.In December, at the CASP13 meeting in Riviera Maya, Mexico, DeepMind beat seasoned biologists at predicting the shapes of proteins, the basic building blocks of disease. The seemingly esoteric pursuit has serious implications: A tool that can accurately model protein structures could speed up the development of new drugs. “Absolutely stunning,” tweeted one scientist after the raw results were posted online. “It was a total surprise,” said conference founder John Moult, a University of Maryland computational biologist. “Compared to the history of what we had been able to do, it was pretty spectacular.” Sorting out the structure of proteins in order to find ways for medicines to attack disease is an enormously complex problem. Researchers still don’t fully understand the rules for how proteins are built. And then there’s the math: There are more possible protein shapes than there are atoms in the universe, making prediction a herculean undertaking of computation. For a quarter century, computational biologists have labored to devise software equal to the task.Enter DeepMind. With limited experience in protein folding — the physical process by which a protein acquires its three-dimensional shape — but armed with the latest neural-network algorithms, DeepMind did more than what 50 top labs from around the world could accomplish. Excitement rippled around the Mayan-themed resort where the meeting was held. Two DeepMind presenters were peppered with questions from scientists about how they had done it. Within hours, the British newspaper The Guardian said DeepMind’s AI could “usher in new era of medical progress.”  In a blog post, the company bragged that its protein models were “far more accurate than any that have come before,” opening up “new potential within drug discovery.”In an email, DeepMind said its scientists were “fully focused on their research” and not available for interviews. DeepMind’s simulation doesn’t yet produce the kind of atomic-level resolution that is important for drug discovery. And though many companies are looking for ways to use computers to identify new medications, few machine-learning-based drugs have progressed to the point of being tested in humans. It will be years before anyone knows whether such software can regularly spot promising therapies that researchers might otherwise have missed.Artificial intelligence is a chic catchphrase in health care, often trotted out as a cure-all for whatever ails the industry. It has been held up as a potential solution to fix cumbersome electronic medical records, speed up diagnosis and make surgery more precise. DeepMind’s victory points to a possible practical application for the technology in one of the most expensive and failure-prone parts of the pharmaceutical business. Some observers said that the fact that a team of outsiders could make such significant progress in untangling one of the most vexing problems of biology is a black eye for researchers in the field. It could also be a portent for the drug industry, which spends billions on research and development, but was beaten to the punch.  Mohammed AlQuraishi, a Harvard computational biology researcher who attended the conference, wrote in a blog post that giant pharmaceutical companies haven’t put a serious effort into protein folding, essentially ceding the ground to tech companies. While drug companies dithered, “Alphabet swoops in and sets up camp right in their backyard,” he wrote.Finding new drugs and bringing them to market is notoriously difficult. According to some estimates, big drugmakers spend more than $2.5 billion to get a new medicine to patients. Just one of every 10 therapies that enters human clinical trials makes it to the pharmacy. And science moves slowly: In the nearly 20 years since the human genome was sequenced, researchers have found treatments for a tiny fraction of the approximately 7,000 known rare diseases.Further, there are approximately 20,000 genes that can malfunction in at least 100,000 ways, and millions of possible interactions between the resultant proteins. It’s impossible for drug hunters to probe all of those combinations by hand.“If we want to understand the other 97 percent of human biology, we will have to acknowledge it is too complex for humans,” said Chris Gibson, the co-founder and Chief Executive Officer of Recursion Pharmaceuticals, a Salt Lake City-based startup that uses machine learning to hunt for new therapies.Companies like Recursion are rapidly luring investors. Venture capitalists poured $1.08 billion into AI and machine-learning startups focused on drug discovery last year, according to data provider PitchBook, up from just $237 million in 2016, and have already put in $699 million more so far this year.  Recursion raised $121 million in its latest financing round, the company said on Monday, from investors including Intermountain Ventures and the Regents of the University of Minnesota. It has a valuation of $646 million, according to PitchBook. “It is a very ambitious company. They are thinking in terms of radically changing the industry,” said Marina Record, an investment manager at Baillie Gifford & Co. in Scotland, which led the funding round.Established drugmakers are racing to ally with companies doing similar work.In April, Gilead Sciences Inc. agreed to a deal with Insitro, a startup led by the former Stanford University machine-learning expert Daphne Koller, to find ways to treat liver disease NASH. AstraZeneca Plc the same month linked up with U.K.-based BenevolentAI to identify treatments for kidney disease and lung fibrosis. In June, GlaxoSmithKline Plc partnered with gene-editing pioneers at the University of California in a $67 million target-hunting collaboration that will use AI.“Where else would you accept a 1-in-10 success rate?” said GlaxoSmithKline senior vice president Tony Wood, who heads medicinal science and technology for the British pharmaceutical giant. “If we could double that to 20% it would be phenomenal.”  Machine-learning methods “are going to be critical” to drug discovery, said Juan Alvarez, an associate vice president for computational chemistry at Merck & Co. The giant drugmaker is developing AI tools to help its chemists accelerate the laborious process of crafting chemicals to block aberrant proteins. Early machine-learning efforts have already contributed to drugs in human testing, while the first drugs based on more advanced neural-network methods could hit trials in several years, Alvarez said.Artificial intelligence could be used to scan millions of high-resolution cellular images—more than humans could ever process on their own—to identify therapies that could make diseased cells healthier in unexpected ways.At Recursion, one of the earliest startups to use such methods, each week robots apply thousands of potential drugs to various types of diseased cells, in 400,000 to 500,000 miniature experiments that generate 5 to 10 million cellular images. Machine-learning algorithms then scan the images, searching for compounds that disrupt disease without harming healthy cells.  The initial algorithms were coded by hand to interpret basic cellular features, but Recursion is increasingly using neural-network methods that directly interpret the images and may spot patterns human programmers wouldn't have looked for. Computer scientists work in tandem with biologists in the laboratory to refine the leads.  The company, which has agreed to rare-disease deals with Takeda Pharmaceutical Co. Ltd. and Sanofi, generated more than 2.5 petabytes of data in the past few years, a total that exceeds roughly the bandwidth of all Hollywood feature films. What the company is doing “just wasn't feasible six, or seven, or eight years ago,” said Gibson, its founder. Gibson first turned to machine learning as a graduate student at the University of Utah searching for treatments for cerebral cavernous malformation, which causes abnormal clumps of leaky blood vessels in the brain. The disorder affects about 1 in 500 people, according to the Angioma Alliance, and while often silent, can lead to seizures, speech or vision difficulties, and devastating brain hemorrhages. About a quarter of patients have a genetic form of the illness that is more likely to cause multiple malformations. Even though the three genes that cause it are known, there are no pharmaceutical treatments. One drug Gibson tested at the University of Utah based on the prevailing understanding of the disease made its symptoms worse in animals.Frustrated, Gibson and his colleagues used open-source machine-learning software for scanning cellular images to probe the effects of 2,100 compounds, searching for ones that improved the appearance and function of blood vessel cells that carried the bad genes. The algorithms pointed to an unexpected chemical that reduced leaky blood vessels in animal tests by 50 percent. That drug, set to enter second-stage human trials next year, led to the founding of Recursion.Other parts of Alphabet, as well as the AI research unit of social-media giant Facebook Inc., which quietly released a paper using deep learning to analyze 250 million protein sequences in April, are creeping into pharmaceutical-company turf. This spring, AI researchers at Google unveiled a neural network that can predict the function of a protein from its sequence of amino acids, which can help biologists understand what a newly discovered protein does. AI proponents say that nobody is talking about taking human researchers out of the equation. The goal is “augmenting and enhancing the decision-making capacity of scientists,” said Jackie Hunter, a former GlaxoSmithKline research executive who now leads clinical programs at BenevolentAI. In the short run, it’s more likely that AI-based simulations will be used to game out whether prospective drugs will be effective before going to a full-on clinical trial.An aerospace company “won’t build and fly a plane without building it on the computer first and simulating it under many conditions,” said Colin Hill of GNS Healthcare, a startup using AI to model disease, whose investors include Amgen Inc. In the future, drugmakers won’t begin clinical trials without a virtual dry run, Hill said.Still, the surprise that unfolded in Mexico has increased the tempo. DeepMind “basically beat everyone by a sizeable margin” said AlQuraishi, the Harvard researcher.  If drugmakers don’t take the threat seriously, he said, they could be left in the dust.  To contact the author of this story: Robert Langreth in New York at rlangreth@bloomberg.netTo contact the editor responsible for this story: Drew Armstrong at, Timothy AnnettFor more articles like this, please visit us at©2019 Bloomberg L.P.

  • Market Exclusive11 hours ago

    Market Morning: Gilead Moves On Galapagos, Hong Kong Keeps Fighting, Trump Tweets

    Gilead Makes Galapagos Move AIDS and hepatitis C giant Gilead (NASDAQ:GILD) is making another move on Galapagos NV (NASDAQ:GLPG) to gain rights outside Europe for certain treatments. Gilead agreed to pay nearly $4 billion plus another $1.1 billion in shares at $158.49 per share, increasing its stake in the company to 22% from 12.3%. The […]The post Market Morning: Gilead Moves On Galapagos, Hong Kong Keeps Fighting, Trump Tweets appeared first on Market Exclusive.

  • Investing.com13 hours ago

    Stocks - Citigroup,, Rise Premarket; Boeing, CIRCOR Fall - Stocks in focus in premarket trading on Monday:

  • TheStreet.com13 hours ago

    Gilead Boosts Investment in Inflammatory Specialist Galapagos by $5.1 Billion

    Gilead Sciences said Monday that it will boost its stake in Belgian listed biotech Galapagos NV by more than $5 billion in a "transformative" deal that could tap new opportunities for the California-based group in fibrosis and arthritis.

  • Gilead to Boost Stake in Galapagos as Part of $5.1 Billion Deal
    Bloomberg15 hours ago

    Gilead to Boost Stake in Galapagos as Part of $5.1 Billion Deal

    (Bloomberg) -- Gilead Sciences Inc. agreed to pay $5.1 billion to raise its stake in biotechnology company Galapagos NV to deepen its research into inflammatory diseases and other disorders, sending the Belgian drugmaker’s stock to an all-time high.The deal is the largest Gilead has executed since new Chief Executive Officer Dan O’Day took the reins in March as he attempts to bolster the San Francisco giant’s drug pipeline. Gilead is in danger of becoming a victim of its own success after launching some of the top drugs of all time, its bestselling hepatitis-C franchise. Sales from those therapies have since declined due to increased competition.Under the agreement, Gilead, which will pay $3.95 billion upfront to Mechelen, Belgium-based Galapagos and invest $1.1 billion to raise its stake to 22% from 12.3%, the companies said in a statement. The investment, at 140.59 euros a share, is 9.7% higher than the Belgian company’s closing price on Friday. Galapagos shares surged as much as 17% on Monday, reaching 149.55 euros a share.“Gilead will significantly expand its pipeline in a smart and financially savvy expanded partnership deal with Galapagos, essentially gaining options on everything in their pipeline without having to acquire the company full out,” Jefferies analysts including Michael J. Yee and Andrew Tsai wrote in a note.As Gilead seeks to fill the growing hole left from its hepatitis drugs, the Galapagos announcement may signal a shift in focus. The smaller biotech has no oncology programs and instead focuses on research into diseases that have to do with inflammation and fibrosis, which is a kind of internal scarring.Gilead has also had research programs in such diseases, including through its collaboration with Galapagos, though some had speculated it may stake its future on cancer. Gilead is already the biggest shareholder of the Belgium company before the increase in stake, according to data compiled by Bloomberg. Now it gets the option to license all of Galapogos’s future, late-stage drug candidates.Gilead CEOO’Day, who joined Gilead from cancer giant Roche AG, said he’s not done making good on his promise to expand the pipeline. He noted the deal almost doubles Gilead’s research capacity and establishes a strong research base in Europe where the company has historically not been as active.“In no way is this the only thing that we’re looking at or the only thing that we’re going to do,” O’Day said in an interview. “You can look at this like it’s the beginning.”Gilead and Galapagos held talks about an expanded partnership prior to O’Day joining the company. He was briefed on those discussions after taking the top job and within the first couple of weeks, got to know the CEO of Galapagos better. Following those talks, the pair decided to being finalizing the agreement.Jobs in EuropeThis is a “science-driven deal,” Onno van de Stolpe, founder and chief executive officer of Galapagos, said in an interview. Gilead will be taking on more of the commercial side for Galapagos, helping the smaller company to focus on research. “We can now do more of what we’re good at.”The money being invested beyond the equity stake will be used largely to double Galapagos’s R&D staff to 1,000 from 500 over an unspecified time, Van de Stolpe said. Those jobs will be added in Belgium, the Netherlands and France. “It’s massive funding -- we don’t have a detailed plan yet on how to spend it,” he said.The pact includes a provision in which Gilead’s stake could rise to 29.9%, if Galapagos shareholders approve two warrants. The companies were already partners on an experimental drug for rheumatoid arthritis. That drug, filgotinib, hit its main goal in a late-stage study in March, triggering the Belgian biotech company’s shares to surge by the most in six months.Galapagos shares have risen 59% since the start of the year, compared with the 5.9% gain in Gilead’s stock.O’Day had a reputation as a dealmaker while at Roche, likely one of the reasons he was selected for Gilead’s top job at a time when the company needs to look externally to drive growth. He said that in this case, the companies opted for a partnership-style deal rather than a full takeover because full mergers can often destroy innovation as research and executive teams disband. Roche’s deal philosophy is much the same with the Swiss giant opting to leave many its units independently managed, even if it owns them in full.Gilead spent about $12 billion to buy Kite Pharma in 2017 for its research into a cutting-edge therapies known as CAR-T. While the treatments can prove near-miraculous for some patients, CAR-Ts have yet to become large sales drivers, falling far below the revenues Gilead needs to replace declining sales from its hepatitis-C franchise.Gilead is not the only large company with fading blockbusters. In June, AbbVie agreed to buy Allergan in a $63 billion megadeal in a bid to replace its bestselling Humira, the bestselling drug in the world. Celgene Corp. faced similar questions as the patent of its bestselling cancer drug aged before Bristol-Myers Squibb agreed to buy it for $74 billion in January.To contact the reporters on this story: Eric Pfanner in London at;Rebecca Spalding in Boston at rspalding@bloomberg.netTo contact the editors responsible for this story: James Ludden at, ;Drew Armstrong at, Kevin Miller, Linus ChuaFor more articles like this, please visit us at©2019 Bloomberg L.P.

  • Gilead invests $5 billion to deepen ties with biotech Galapagos
    Reuters16 hours ago

    Gilead invests $5 billion to deepen ties with biotech Galapagos

    The move will bring Gilead's new chief executive Daniel O'Day growth opportunities in Galapagos's specialist areas including fibrosis and arthritis, and give Galapagos deep funds to develop and commercialize its drugs. AbbVie's Humira, used to treat rheumatoid arthritis and spondylitis, racked up nearly $20 billion in sales in 2018, while Amgen and Pfizer's Enbrel still brings in $7 billion annually after 20 years on the market. As part of the deal, Gilead will spend $1.1 billion to lift its Galapagos stake to 22% from 12.3%.

  • Reuters21 hours ago

    PRESS DIGEST- Financial Times - July 15

    British digital bank Revolut is nearing the appointment of Martin Gilbert as its new chairman as the bank looks to strengthen its governance. Gilead Sciences will invest $5.1 billion in Galapagos NV to raise its stake in the Belgian biotech group and access its pipeline of drugs under development. GlaxoSmithKline Plc is to hire Jonathan Symonds, the current deputy group chairman of HSBC, as its new chairman to oversee the British drugmaker's break-up.

  • GlobeNewswireyesterday


    - Gilead to Make $3.95 Billion Upfront Payment and $1.1 Billion Equity Investment - - Gilead Gains Access to Galapagos` Differentiated Drug Discovery Platform and Current and Future Pipeline Outside of ...

  • Business Wireyesterday

    Gilead and Galapagos Enter Into Transformative Research and Development Collaboration

    Gilead Sciences, Inc. (GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced that they have entered into a 10-year global research and development collaboration. Through this agreement, Gilead will gain access to an innovative portfolio of compounds, including six molecules currently in clinical trials, more than 20 preclinical programs and a proven drug discovery platform.

  • Financial Timesyesterday

    Gilead to raise stake in Belgian biotech in $5.1bn deal 

    US drugmaker Gilead Sciences has agreed a $5.1bn deal to increase its stake in Belgian biotech group Galapagos and gain access to a pipeline of drugs that are under development. Gilead will acquire the rights outside Europe to two additional drugs that are in development, which target osteoarthritis and lung scarring. The American company is paying an upfront fee of $3.95bn, and will also invest $1.1bn to nearly double its stake in Galapagos to 22 per cent. It will make additional payments if the two experimental drugs named in the deal are approved in the US.